Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis

• Principais autores: A. V. Samtsov (Autor), V. R. Khairutdinov (Autor), A. L. Bakulev (Autor), A. A. Kubanov (Autor), A. E. Karamova (Autor), A. V. Artem'eva (Autor), T. V. Korotaeva (Autor)
• Formato: Livro
• Publicado em: State Scientific Center of Dermatovenereology and Cosmetology, 2018-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Recent studies on psoriasis confirmed that interleukin-17 (IL-17) plays a crucial role in the progression of the disease. Inhibition of this cytokine leads to significant improvement in the course of the disease. Russian biotechnology company BIOCAD have developed an innovative drug, a monoclonal an...